质子泵抑制剂的研发进展被引量：22

The Progress in Research of Proton Pump Inhibitor

下载PDF

导出

摘要自第一个质子泵抑制剂(PPI)奥美拉唑于1988年上市以来,PPI已成为酸相关性疾病治疗的首选药物。PPI抑制胃壁细胞泌酸的最终环节,抑酸能力大大超过H2受体拮抗剂等传统抑酸药,临床应用广泛。近年来PPI研发不断创新,新一代PPI在治疗胃食管反流病及其他酸相关性疾病时具有明显优势,起效更快,抑酸效果更好、更彻底,夜间酸突破短,药物代谢对CYP2C19酶的依赖性小,不受其基因多态性的影响。 Since the first proton pump inhibitor （Omeprazole） came into the market in 1988,PPIs have been omsidered as the drugs of first choice for treatment of patients with various acid-related diseases. PPIs block the final step of acid secretion of gastric parietal cells,and have much more potent action than traditional acid inhibitors,like 142-receptor antagonist.In the recent years,there are great development in the research of PPIs. The new-generation PPIs have outstanding advantages in the treatment of GERD and other acid-related diseases,with more rapid and effective inhibition of acid secretlon, shorter acid breakthrough in the night, and less dependence on the cytochromeP450 and gene polymorphism.

作者梁小燕高青

机构地区重庆医科大学附属第一医院消化科

出处《医学综述》 2007年第4期245-247,共3页 Medical Recapitulate

关键词质子泵质子泵抑制剂酸相关性疾病 Proton pump Proton pump inhibitor Acid-related diseases

分类号 R975.2 [医药卫生—药品]

引文网络
相关文献

参考文献17

1Howden CW.Review article:immediate-release proton-pump inhibitor therapy-potential advantages[J].Aliment Pharmacol Ther,2005,22(Suppl 3):25-30.
2赵飞,张建中,曾浔.新视角——质子泵抑制剂及其体外抑制幽门螺杆菌作用研究进展[J].中国全科医学,2005,8(11):936-938. 被引量：24
3Baldi F.Lansoprazole ora-dispersible tablet:pharmacokinetics and therapeutic use in acid-related disorders[J].Drugs,2005,65 (10):1419-1426.
4Kawakami Y,Akahanc T,Yamaguchi M.In vitro activities of rabeprazole,a novel proton pump inhibitor and its thiocther derivative alone and in combination with other anti-micobials against recent clinical isolates of Helicabacter pylori[J].Antimicrob Agent Chemother,2000,44(2):458-461.
5Ishiraki T,Horat Y.Cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole[J].Aliment Pharmacol Ther,1999,13 (Suppl3):27-30.
6Chiverton SG,Howden CW,Burget DW.Omeprazole (20 mg) daily given in the morning or evening:a comparison of effects on gastric acidity,and plasma gastrin and omeprazole concentration[J].Aliment Pharmacol Ther,1992,6(1):103-111.
7Hom J.The proton-pump inhibitors:similarities and difference[J].Clin Ther,2000,22(3):266-280.
8Gillen D,Wirz AA,Ardill JE,et al.Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status[J].Gastroenterology,1999,116(2):239-247.
9Jones MP,Shah D,Ebert CC.Effects of rabeprazole sodium emptying,electmgastrography,and fullness[J].Dig Dis Sci,2003,48(1):69-73.
10孙忠实.质子泵抑制剂的新突破——雷贝拉唑[J].中国药学杂志,2003,38(4):307-309. 被引量：89

二级参考文献37

1王瑞彬,丁惟培.质子泵抑制剂的开发及研究现状[J].中国药物化学杂志,1995,5(1):73-78. 被引量：12
2SavarinoV.抑酸治疗的新纪元[N].中国医学论坛报,2001.09—06(4).
3Johnstone D, Berger C, Fleckman P, et al. Acute ful minant hepattis after treatment with rabeprazole and tebinafine[J]. Arch Intern MM .2001.161 : 1677.
4Richardson P, Hawkey CJ, Stack WA. Proton pump inhititors[J]. Drugs, 1998,56 : 307.
5Tytgat GNJ. Shortcomings of the first-generation proton pump inhibitors[J]. Eur J Gastroenterol Hapatol, 2001,13 (Suppl 1):29.
6Sachs G, Shin JM. The Pharmacology of the gastric acid pump.The H^+ , K^+ ATPase[J]. Annu Rev Phamacol Toxicol, 1995,35 : 277.
7Besancon M,Simon A,Sachs G, et al. Sites of reaction of the gastric H^+ , K ^+ ATPase with extraytoplasmic thiol regents[ J ]. J Biol Chen, 1997,272 : 22438.
8Carswell CI ,Goa KL. Rabeprazole. an update of its use in acid-related disorders[J]. Drugs ,2001,61:2327.
9LangtryHD,Markham A. Rabeprazole:a review of its use in acidrelated gastrointestinal disorders[J]. Drugs, 1999,58 : 725.
10Prakash A, Faulds D. Rabeprazole[ J ]. Drugs, 1998,55 : 261.